Shots:

• The P-II LIMT study involves assessing of (peg INF-Lambda) Lambda 120/180 μg SC IV qw for 48wks. in ratio (1:1) (N=33) in patients with chronic HDV- testing safety- efficacy & tolerability. In the study- patients received continuous anti-hepatitis B virus nucleos(t)ide analog
• P-II LIMT study results (120/180mg): mean decline in HDV-RNA (-1.5 log10- -2.4 log10)- ≥2 log10 decline (42.9%- 60%); HDV-RNA -ve at end of treatment (14.3%- 40%)
• In 2016- Eiger gained global rights to Lambda from BMS. Additionally- P-II LIFT (Lambda InterFeron combo-Therapy) is conducted at NIH assessing Lambda + Lonafarnib boosted with Ritonavir with 1EP ≥ 2 log decline in HDV RNA & 2EP > 2 point improvement in histological activity index and no progression in fibrosis

Ref: Eiger Pharmaceuticals | Image: RTE